The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Sustained improvement in skin symptoms up to 5 years1,a


aPALACE 1-3 study. Data as observed; includes all patients with baseline psoriasis BSA >3 who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Patients with BSA ≥3 at baseline: OTEZLA 30 mg BID, n = 92/167 (55.1%); placebo, n = 94/169 (55.6%).

  • OTEZLA provided sustained improvement in skin symptoms for up to 5 years2

OTEZLA is also indicated for moderate to severe plaque psoriasis3

See the OTEZLA difference

Real psoriasis patients, real pictures.*

Actual patient with psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.


Actual patient with psoriasis who achieved a 75% decrease in PASI after 16 weeks on OTEZLA®. Please see full Important Safety Information.

Week 16 PASI-75 result

Individual results may vary.

*Actual real-world OTEZLA patient. Property of Amgen Inc.

BID, twice daily; BSA, body surface area; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; PASI, Psoriasis Area and Severity Index.


  1. Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis. Arthritis Res Ther. 2019;21(1):118.
  2. Edwards CJ, et al. Apremilast is associated with long-term (4-year) DAS-28 (CRP) remission and improvements in skin disease: results from a phase III study in DMARD/biologic-experienced patients with active psoriatic arthritis. Ann Rheum Dis. 2017;76 (suppl 2): Abstract FRI0487.
  3. OTEZLA Summary of Product Characteristics. Amgen Europe B.V. Minervum 7061, 4817 ZK Breda, The Netherlands; 2020.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.